Broadcast

e-SPACE CRM 2026 – Day Two

Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira

Broadcast

e-SPACE CRM 2026 – Day One

Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira

Broadcast

Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care

Vijay Chopra, Javed Butler, Dinesh Khullar , et al

Watch time: 1h 4m 2s

About

Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and prevents cardiovascular disease outcomes.

Most hypertensive patients will need a combination of antihypertensive agents to achieve the therapeutic goals. Recent guidelines recommend initiating treatment with two drugs in those patients with a systolic blood pressure >20 mmHg and/or a diastolic blood pressure >10 mmHg above the goals, and in those patients with high cardiovascular risk. In addition, approximately 25% of patients will require three antihypertensive agents to achieve the therapeutic targets.

Articles

Current Thinking in Acute Congestive Heart Failure and Pulmonary Edema

Citation:

US Cardiology 2004;1(1):1-6

Pulmonary Hypertension in Heart Failure Patients

Published:

09 April 2020

Citation:

Cardiac Failure Review 2020;6:e05.

PVI Versus Amiodarone in AF and CHF

Published:

09 April 2020

Citation:

Cardiac Failure Review 2020;6:e04.